Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

• Autori principali: Shuwen Jiang (Autore), Xiangkun Li (Autore), Weifang Xue (Autore), Sumei Xia (Autore), Jian Wang (Autore), Yang Sai (Autore), Guangxiu Dai (Autore), Weiguo Su (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...